Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210,904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. Jain P, et al. Among authors: wang x. Am J Hematol. 2015 Jun;90(6):471-7. doi: 10.1002/ajh.23978. Epub 2015 Mar 30. Am J Hematol. 2015. PMID: 25683856 Free PMC article.
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Estey EH, et al. Blood. 2002 Jun 15;99(12):4343-9. doi: 10.1182/blood.v99.12.4343. Blood. 2002. PMID: 12036860 Free article. Clinical Trial.
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. Wierda W, et al. Among authors: wang x. Cancer. 2006 Jan 15;106(2):337-45. doi: 10.1002/cncr.21554. Cancer. 2006. PMID: 16353201 Free article.
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Wierda WG, et al. Among authors: wang x. Blood. 2007 Jun 1;109(11):4679-85. doi: 10.1182/blood-2005-12-051458. Epub 2007 Feb 13. Blood. 2007. PMID: 17299097 Free article.
Aurora-A kinase nuclear expression in chronic lymphocytic leukemia.
Inamdar KV, O'Brien S, Sen S, Keating M, Nguyen MH, Wang X, Fernandez M, Thomazy V, Medeiros LJ, Bueso-Ramos CE. Inamdar KV, et al. Among authors: wang x. Mod Pathol. 2008 Dec;21(12):1428-35. doi: 10.1038/modpathol.2008.173. Epub 2008 Oct 17. Mod Pathol. 2008. PMID: 18931650 Free article.
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Borthakur G, et al. Among authors: wang x. Cancer. 2008 Dec 1;113(11):3181-5. doi: 10.1002/cncr.23927. Cancer. 2008. PMID: 18932257 Free PMC article. Clinical Trial.
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Wierda WG, et al. Among authors: wang x. J Clin Oncol. 2009 Apr 1;27(10):1637-43. doi: 10.1200/JCO.2008.18.1701. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224852 Free PMC article.
210,904 results
You have reached the last available page of results. Please see the User Guide for more information.